ストックスクリーナーアプリを入手
48.81
0.14%
-0.07
アフターアワーズ：
48.93
0.12
+0.25%
前日終値:
$48.88
開ける：
$48.895
24時間の取引高:
2.97M
Relative Volume:
0.58
時価総額：
$98.49B
収益：
$42.06B
当期純損益:
$7.96B
株価収益率:
13.92
EPS:
3.5062
ネットキャッシュフロー:
$5.64B
1週間 パフォーマンス:
+0.83%
1か月 パフォーマンス:
+1.54%
6か月 パフォーマンス:
+14.87%
1年 パフォーマンス:
+42.84%
1日の値動き範囲:
$48.55
$48.99
1週間の範囲:
$47.20
$48.99
52週間の値動き範囲:
$31.71
$49.31
Gsk Plc Adr Stock (GSK) Company Profile
GSK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
48.81 | 98.63B | 42.06B | 7.96B | 5.64B | 3.5062 |
|
LLY
Lilly Eli Co
|
1,027.51 | 903.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
211.58 | 505.98B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.32 | 395.86B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.57 | 253.97B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.30 | 245.75B | 63.90B | 19.05B | 13.05B | 7.5596 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-25 | アップグレード | BofA Securities | Underperform → Neutral |
| 2025-06-03 | ダウングレード | Berenberg | Buy → Hold |
| 2025-04-15 | 開始されました | Exane BNP Paribas | Neutral |
| 2025-02-12 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-11-15 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-11-12 | ダウングレード | Jefferies | Buy → Hold |
| 2024-10-31 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-07-08 | ダウングレード | UBS | Buy → Neutral |
| 2024-05-30 | 開始されました | Goldman | Neutral |
| 2024-03-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-02-13 | アップグレード | Citigroup | Neutral → Buy |
| 2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 再開されました | UBS | Buy |
| 2024-01-03 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-03-17 | アップグレード | Deutsche Bank | Hold → Buy |
| 2023-02-27 | 再開されました | Goldman | Buy |
| 2023-01-03 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-12-05 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-11-11 | ダウングレード | UBS | Neutral → Sell |
| 2022-09-15 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | ダウングレード | Jefferies | Buy → Hold |
| 2022-08-05 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-07-21 | 再開されました | Citigroup | Neutral |
| 2022-02-11 | ダウングレード | DZ Bank | Buy → Hold |
| 2021-11-05 | アップグレード | Barclays | Underweight → Equal Weight |
| 2021-06-24 | アップグレード | Deutsche Bank | Sell → Hold |
| 2021-03-23 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2021-01-20 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | 開始されました | Deutsche Bank | Hold |
| 2020-11-02 | アップグレード | Liberum | Hold → Buy |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2020-02-12 | ダウングレード | Shore Capital | Hold → Sell |
| 2020-01-16 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2019-12-02 | 開始されました | SVB Leerink | Outperform |
| 2019-11-21 | アップグレード | UBS | Neutral → Buy |
| 2019-10-11 | アップグレード | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | 再開されました | Citigroup | Neutral |
| 2019-09-03 | アップグレード | Societe Generale | Sell → Buy |
| 2019-08-13 | 再開されました | JP Morgan | Neutral |
| 2019-06-17 | 再開されました | Morgan Stanley | Underweight |
| 2019-03-08 | ダウングレード | Shore Capital | Buy → Hold |
| 2019-02-22 | ダウングレード | UBS | Buy → Neutral |
| 2019-01-14 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | 再開されました | Jefferies | Buy |
| 2018-10-09 | 開始されました | Guggenheim | Neutral |
| 2018-08-30 | ダウングレード | Liberum | Buy → Hold |
| 2018-04-04 | アップグレード | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | アップグレード | Kepler | Reduce → Hold |
すべてを表示
Gsk Plc Adr (GSK) 最新ニュース
GSK plc Stock News Today (Dec. 13, 2025): EU and FDA Decisions Put Pipeline Momentum Back in Focus - ts2.tech
GSK Gets FDA Nod for Blujepa in Uncomplicated Urogenital Gonorrhea - Finviz
GSK Expands Use Of Urinary Tract Infection Drug For Gonorrhoea Patients - Benzinga
GSK (GSK) Scores Win in the Form of Lung Cancer Drug's Orphan Drug Designation - Finviz
GSK (GSK) Scores Win in the Form of Lung Cancer Drug’s Orphan Drug Designation - Insider Monkey
GSK (NYSE:GSK) Share Price Passes Above 200-Day Moving Average – Here’s Why - Defense World
GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally - ts2.tech
GSK's Risvutatug Rezetecan Gets FDA's Orphan Drug Tag in Lung Cancer - Finviz
Is GSK PLC Gaining or Losing Market Support? - Sahm
13 Best ADR Stocks to Invest In - Insider Monkey
J.P. Morgan Maintains a Sell Rating on GSK plc (GSK) - Finviz
GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating - ts2.tech
GSK Stock Outlook December 2025: Q3 Beat, Buybacks and Big FDA Decisions Shape 2026 Forecasts - ts2.tech
AstraZeneca, GSK Among Executives Asked To Help Redesign UK Pricing Rules-Report - Sahm
Analysts Offer Predictions for GSK's Q2 Earnings (NYSE:GSK) - MarketBeat
Quantbot Technologies LP Has $5.33 Million Stock Holdings in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK Stock Near 52‑Week High as FDA Decisions and CEO Transition Loom (LON:GSK, NYSE:GSK) - ts2.tech
Here's Why GSK (GSK) is a Strong Growth Stock - Yahoo Finance
GSK PLC Sponsored ADR $GSK Shares Acquired by Fisher Asset Management LLC - MarketBeat
GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025 - ts2.tech
GSK Stock on 1 December 2025: Big 2025 Rally, Blenrep’s Comeback and a New CEO – What Investors Need to Know Now - ts2.tech
GSK PLC Sponsored ADR (NYSE:GSK) Receives Average Rating of “Hold” from Analysts - Defense World
GSK plc Stock Today, 28 November 2025: Buybacks, ‘Hold’ Ratings and Pipeline Momentum Keep Shares Near Highs - ts2.tech
Rep. Lisa C. McClain Sells Off Shares of GSK PLC Sponsored ADR (NYSE:GSK) - Defense World
GSK PLC Sponsored ADR (NYSE:GSK) Receives Average Rating of "Hold" from Analysts - MarketBeat
Looking To Buy GSK Plc ADR (GSK)? Read This First - fostersleader.com
GSK News Today (26 November 2025): Medicare Slashes Prices on Trelegy, Berenberg Lifts Target, and Buybacks Signal Confidence - ts2.tech
Rep. Lisa C. McClain Buys GSK PLC Sponsored ADR (NYSE:GSK) Stock - MarketBeat
Barclays PLC Share Price Today, 25 November 2025: BARC Jumps Above 409p as UK Budget Tax Fears Ease - ts2.tech
GSK (NYSE:GSK) Stock Unloaded Rep. Lisa C. McClain - Defense World
SG Americas Securities LLC Has $995,000 Stock Holdings in GSK PLC Sponsored ADR $GSK - MarketBeat
Zacks Research Issues Pessimistic Estimate for GSK Earnings - Defense World
Why GSK (GSK) is a Top Value Stock for the Long-Term - Yahoo Finance
Zacks Research Weighs in on GSK’s FY2025 Earnings (NYSE:GSK) - Defense World
JPMorgan Lowers GSK Price Target, Maintains Underweight Rating - Finviz
Alector Stock Plummets 63% in a Month: Here's What You Need to Know - Finviz
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
GSK PLC Share Price: What to Know Before the London Market Opens on 17 November 2025 - ts2.tech
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal - Finviz
The Best Healthcare Stock to Hold in Uncertain Times - Finviz
Why GSK (GSK) is a Top Growth Stock for the Long-Term - Yahoo Finance
GSK (NYSE:GSK) Sets New 12-Month HighTime to Buy? - MarketBeat
AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study - Sahm
Looking Into GSK PLC's Recent Short Interest - Sahm
3 Dividend Stocks for November 2025 - Morningstar
10 Best Value Stocks to Buy for the Long Term - Morningstar
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of "Hold" by Analysts - MarketBeat
Arkadios Wealth Advisors Acquires 6,734 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
GSK PLC Sponsored ADR Plans Quarterly Dividend of $0.42 (NYSE:GSK) - MarketBeat
GSK's Vaccine and HIV Portfolios Support Ongoing Innovation in Oncology and Immunology - Morningstar
GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View - TradingView
Gsk Plc Adr (GSK) 財務データ
収益
当期純利益
現金流量
EPS
0.37%
0.19%
大文字化:
|
ボリューム (24 時間):